Stockscreener 앱 받기
88.07
2.18%
-1.96
전일 마감가:
$90.03
열려 있는:
$90.02
하루 거래량:
17.27M
Relative Volume:
1.88
시가총액:
$130.56B
수익:
$19.35B
순이익/손실:
$2.78B
주가수익비율:
47.11
EPS:
1.8696
순현금흐름:
$3.82B
1주 성능:
-9.80%
1개월 성능:
-5.25%
6개월 성능:
-14.65%
1년 성능:
-10.29%
1일 변동 폭
$88.04
$90.02
1주일 범위
$87.22
$97.90
52주 변동 폭
$85.98
$109.50
보스턴사이언티픽 Stock (BSX) Company Profile
명칭
Boston Scientific Corp
전화
508-683-4000
주소
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
BSX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
88.07 | 133.46B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
ABT
Abbott Laboratories
|
121.76 | 214.80B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
363.78 | 138.62B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
96.76 | 126.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.35 | 49.03B | 5.88B | 1.34B | 799.60M | 2.3489 |
보스턴사이언티픽 Stock (BSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-03 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-09-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-06-16 | 개시 | Leerink Partners | Outperform |
| 2025-04-16 | 업그레이드 | Needham | Hold → Buy |
| 2025-01-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-10-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-02-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-06-30 | 개시 | CL King | Buy |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-12-22 | 개시 | Mizuho | Neutral |
| 2022-12-20 | 재개 | Citigroup | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-06 | 개시 | Wolfe Research | Outperform |
| 2022-05-27 | 업그레이드 | Needham | Hold → Buy |
| 2022-04-13 | 재개 | Truist | Buy |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-05-26 | 다운그레이드 | Needham | Buy → Hold |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2020-09-17 | 개시 | Truist | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Peer Perform |
| 2020-04-22 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Buy |
| 2019-12-30 | 재확인 | Cowen | Outperform |
| 2019-12-19 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2019-09-05 | 재개 | JP Morgan | Overweight |
| 2019-09-03 | 재개 | Barclays | Overweight |
| 2019-05-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-11-28 | 개시 | UBS | Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-10-02 | 재확인 | Morgan Stanley | Overweight |
| 2018-09-07 | 재확인 | Needham | Strong Buy |
| 2018-09-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-07-06 | 재확인 | Needham | Strong Buy |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-04-26 | 재확인 | Needham | Strong Buy |
모두보기
보스턴사이언티픽 주식(BSX)의 최신 뉴스
Penumbra Shares Soar Pre-MarketWhat Is The Boston Scientific Agreement? - Menafn
Is Boston Scientific Corporation (NYSE:BSX) Worth US$88.1 Based On Its Intrinsic Value? - Yahoo Finance
Boston Scientific (BSX) Expands Urology Portfolio with Valencia Deal, Analysts Emphasize Organic Growth - Insider Monkey
Halper Sadeh LLC Encourages PEN, CVGW, AVO Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
A big acquisition decades ago almost broke Boston Scientific. Its CEO says this time is different. - Star Tribune
Med tech company Boston Scientific readies for new Austin offices - MSN
RTW Biotech Opp.Boston Scientific to acquire Penumbra - Research Tree
Boston Scientific (BSX) stock falls again as traders digest $14.5 billion Penumbra buy - TechStock²
Penumbra Inc. to be Sold to Boston Scientific for $374 per Share - Intellectia AI
Boston Scientific to buy Penumbra in $14.5 billion deal - AOL.com
This is Why Wall Street Firms are Bullish on Boston Scientific Corporation (BSX) - Finviz
Truist Securities reiterates Buy rating on Boston Scientific stock - Investing.com
Boston Scientific looks to nearly double size of Minnesota facility - MassDevice
Boston Scientific (BSX): Oppenheimer Adjusts Price Target, Maint - GuruFocus
Down 6.3% in 4 Weeks, Here's Why Boston Scientific (BSX) Looks Ripe for a Turnaround - Yahoo Finance
Boston Scientific (NYSE:BSX) Price Target Lowered to $100.00 at Oppenheimer - MarketBeat
Oppenheimer Adjusts Price Target on Boston Scientific to $100 From $125, Maintains Outperform Rating - marketscreener.com
Leerink Partners downgrades Penumbra stock following Boston Scientific deal - Investing.com
RTW Biotech Opportunities Portfolio Company Penumbra To Be Acquired By Boston Scientific - DirectorsTalk Interviews
Boston Scientific to acquire Penumbra for $14.5 billion - Investing.com
Truist Securities downgrades Penumbra stock to Hold following Boston Scientific acquisition - Investing.com
Boston Scientific Target of Unusually High Options Trading (NYSE:BSX) - MarketBeat
Boston Scientific Buys Heart Device Maker Penumbra For $14.5 Billion - Baystreet.ca
Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead - TechStock²
Boston Scientific to acquire Penumbra for portfolio of vascular treatments - MLex
Boston Sci swings for the fences with $14.5B Penumbra buy - BioWorld MedTech
One of Alameda's largest companies agrees to be acquired for $14.5 billion - The Business Journals
The Beat: Boston Sci expanding in Maple Grove, TurnSignl demand spikes with ICE - The Business Journals
Why Boston Scientific (BSX) Stock Is Down Today - Finviz
Boston Scientific to acquire California manufacturer for $14.5B - Worcester Business Journal
Boston Scientific (BSX) Plans to Acquire Penumbra for $374 Per S - GuruFocus
Boston Scientific stock holds Buy rating at Needham after Penumbra acquisition - Investing.com
JPM26: Boston Scientific acquires Penumbra in $14.5bn deal - Yahoo Finance
Boston Scientific (NYSE:BSX) Shares Gap DownShould You Sell? - MarketBeat
Boston Scientific to acquire Penumbra in $14.5B deal - Proactive financial news
Boston Scientific beefs up heart device portfolio with $14.5 billion Penumbra deal - Reuters
Boston Scientific pays $14.5B for California medical device company - The Business Journals
Boston Scientific Corp (BSX) Shares Down 4.66% on Jan 15 - GuruFocus
Boston Scientific stock rises as Stifel praises Penumbra acquisition - Investing.com
Morgan Stanley sees Boston Scientific stock as undervalued after Penumbra deal - Investing.com
Boston Scientific beefs up heart device portfolio with $14.5 billion Penumbra deal By Reuters - Investing.com
Boston Scientific (BSX) Announces Acquisition of Penumbra - GuruFocus
Boston Scientific (BSX) Shares Drop on Penumbra Acquisition - GuruFocus
Penumbra Shares Are Rising Today — What Is The Boston Scientific Agreement? - Stocktwits
Boston Scientific Agrees to Buy Penumbra in $14.6 Billion Cardiovascular Deal - GuruFocus
Boston Scientific to buy Penumbra for more than $14B - Modern Healthcare News
Boston Scientific to Acquire Penumbra in $14.5 Billion Cash-Stock Deal - marketscreener.com
Boston Scientific To Acquire Penumbra; Stock Soars - Nasdaq
Boston Scientific Buys Device Maker Penumbra for $14.5 Billion - Bloomberg.com
Boston Scientific to Buy Penumbra in Deal Reflecting $14.5 Billion Enterprise Value - marketscreener.com
3 Firms Advise On Boston Scientific's $14.5B Penumbra Deal - Law360
보스턴사이언티픽 (BSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.26%
0.36%
자본화:
|
볼륨(24시간):